

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 June 2006 (22.06.2006)

PCT

(10) International Publication Number  
**WO 2006/063858 A1**

- (51) International Patent Classification:  
A61K 9/50 (2006.01) A61K 31/55 (2006.01)
- (21) International Application Number:  
PCT/EP2005/013670
- (22) International Filing Date:  
15 December 2005 (15.12.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0427455.1 15 December 2004 (15.12.2004) GB
- (71) Applicant (for all designated States except US):  
JAGOTEC AG [CH/CH]; Eptingerstrasse 51, CH-4132 Mutenz (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GRENIER, Pascal [FR/FR]; Résidence la Clef des Champs, 5, Rue des Vignes, F-68510 Kappelen (FR). TAILLEMITE, Julien [FR/FR]; 2, Rue de Mulhouse, F-68330 Huningue (FR). SERREAU, Severine [FR/FR]; 19, Rue Theo Bachmann, F-68300 St. Louis (FR). NHAMIAS, Alain [FR/FR]; 10, Rue des Bleuets, F-68870 Bartenheim (FR).
- (74) Agents: CRUMP, Julian, Richard, John et al.; Mintz Levin Cohn Ferris Glovsky & Popeo Intellectual Property LLP, The Rectory, 9 Ironmonger Lane, London EC2V 8EY (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITION CONTAINING COATED, FLOATING PARTICLES

(57) Abstract: A dosage form exhibiting delayed transit time through the GI tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating.



WO 2006/063858 A1

## PHARMACEUTICAL COMPOSITION CONTAINING COATED, FLOATING PARTICLES

The present invention is concerned with controlled release dosage forms for the targeted delivery of drugs to the upper part of the gastro-intestinal (GI) tract.

Dosage forms able to target drug delivery to the upper part of the GI tract are attractive for a number of reasons. In particular, many drugs display better and/or faster absorption at the duodenum or parts of the intestine proximate the duodenum. Furthermore, the absorption gradient for many drugs shows a very steep decline from sites of the intestine proximate the duodenum to areas distal therefrom.

Conventional controlled release dosage forms can exhibit significant variance in bioavailability, particularly if there is a steep absorption gradient along the intestine. Similarly, variable bioavailability might occur if a drug substance is unstable in the intestinal environment.

Moreover, because the transit time of a dosage form through the stomach is rapid under fasted conditions as compared with fed conditions, conventional controlled release dosage forms often display marked variance in bioavailability between the fed and fasted states.

As a result, many conventional controlled release dosage forms fail in development because of poor pharmacokinetics, and many potential useful therapies are lost to the public as a result.

Having regard to the foregoing problems, it would be desirable if a dosage form could be held above an optimal site of absorption for an extended period of time in order that a significant amount, preferably all or substantially

**CONFIRMATION COPY**

all, of the drug can be released for absorption at or near this site.

5 The idea of delaying the transit time of a dosage form through the GI tract as a result of prolonging its gastric residence is known in the art and there have been several approaches previously suggested for achieving this.

10 One approach relies on a unitary dosage form that is so large that its passage through the duodenal sphincter is restricted. This approach relies on the dosage form expanding in the stomach after ingestion.

15 A problem with this approach is that the unitary dosage form must reliably swell or expand to prevent its quick passage through the pyloric sphincter. Unless the expansion mechanism is entirely reliable, one could anticipate patient compliance issues and variability in dosing: For example, premature expansion of the dosage form could be very uncomfortable for  
20 a patient presented with swallowing difficulties, whereas delayed expansion could result in the dosage form passing through the pylorus without any delay. In fact, in view of the muscular nature of the stomach wall, even dosage forms larger than the pylorus cut-off size can be squeezed through  
25 the pylorus under mechanical action.

Another approach relies on the dosage form presenting a mucoadhesive outer coating that adheres to the stomach wall such that it is retained in the stomach for a prolonged  
30 period of time. However, a problem with this approach is that the stomach wall is not rigid. The wall is subject to propulsive motor activity. Further, there is a large secretory activity of the stomach mucosa. Still further, the dosage form cannot be attached to the wall with a defined

application pressure. As a result, variable residence times in the stomach can be anticipated as a result of unpredictable physiological factors.

5 An additional problem that is common to all of the foregoing approaches is that formulation requirements necessary to obtain the mucoadhesion, or size expansion, may not be consistent with the formulation releasing the drug with a desired release profile. It stands to reason that there is  
10 little point in delaying the transit time of a dosage form if, as a result, drug is released from that dosage form in an uncontrollable or undesired manner.

It has now been found that it is possible to provide dosage  
15 forms that exhibit slow transit times through the GI tract, and which also exhibit zero order, or substantially zero order, release kinetics by presenting such dosage forms in buoyant, multiparticulate forms such, for example, as beads or microspheres. Such dosage forms do not require any  
20 mucoadhesive outer coating.

According to a first aspect of the present invention therefore there is provided a dosage form comprising a plurality of particles that are buoyant in aqueous media,  
25 said particles comprising a drug-containing inner core, an intermediate layer surrounding said core and a drug release rate-controlling coating surrounding said intermediate layer.

Said inner core may comprise at least one matrix-forming  
30 polymer and at least one drug. Said at least one matrix-forming polymer may be chosen to be gellable and/or soluble in aqueous media. Examples of suitable matrix-forming polymers include: hydroxyalkyl cellulose, e.g. hydroxypropylcellulose and hydroxypropylmethylcellulose;

poly(ethylene)oxide; alkylcellulose, e.g. ethylcellulose and methylcellulose; carboxymethylcellulose; hydrophilic cellulose derivatives; polyethylene glycol; polyvinylpyrrolidone; cellulose acetate; cellulose acetate butyrate; cellulose acetate phthalate; cellulose acetate trimellitate; polyvinylacetate phthalate; hydroxypropylmethylcellulose phthalate; hydroxypropylmethylcellulose acetate succinate; poly(alkyl methacrylate); carboxyvinyl polymers; polyvinyl alcohols; glucans; scleroglucans; chitosans; mannans; galactomannans; xantan gums; carrageenin; carrageenans; amylose; alginic acid, and salts and derivatives thereof; and poly (vinylacetate).

15 The nature of the polymer or polymers selected depends upon the desired gellable and/or solubility properties of the matrix; the composition of the inner core can be adjusted to achieve any desired result.

20 Similarly, the amount of said at least one matrix-forming polymer employed is be influenced by the composition of the inner core, and the desired gellability and/or solubility properties. Generally however, said at least one matrix-forming polymer may be present in amounts of 20 to 90% by weight of the inner core; more particularly 40 to 70% by weight.

Said at least one drug may be dispersed or dissolved within the matrix forming polymer. The at least one drug may be present in an amount of from 0.1 to 80% based on the weight of the dosage form; more particularly from 1 to 50% wt.

Any drug that can usefully be released and absorbed in the stomach, or in regions of the intestine in or near to the duodenum, may be employed in the present invention.

5 The present invention may be particularly useful for delivering drugs that are poorly absorbed in the lower gastrointestinal tract, but well absorbed in the upper gastrointestinal tract, or drugs that exhibit poor solubility such that the increased retention time in the stomach  
10 provided by the dosage forms of the present invention allows for a greater quantity of drug to be delivered from the dosage form than would otherwise occur.

Typically, antiviral, antifungal and antibiotic agents, e.g.  
15 sulfonamides, quinolones, penicillins, cephalosporins, aminoglycosides and tetracyclines, are representative classes of agents for which the invention may be particularly useful.

Such antibiotic agents may include, for example,  $\beta$ -lactam  
20 antibiotics, vancomycin, clidamycin, erythromycin, trimethoprim-sulfamethoxazole, rifampin, ciprofloxacin, amoxicillin, clindamycin, ceftriaxone, cefotaxime, chloramphenicol, clindamycin, cefoxitin, doxycycline, spectinomycin, ofloxacin, rifampin, minocycline, doxycycline,  
25 aztreonam, imipenem, meropenem, nitrofurantoin, azithromycin, atovaquone, trimetrexate, dapsone, primaquin, trimetrexate, ketoconazole, floconazole, amphotericin B, itraconazole, trifluridine, foscarnet, zidovudine, amantadine, interferon alfa, sulfonamides such as sulfisoxazole, sulfadiazine, and  
30 sulfasalazine, quinolones and fluoroquinolones such as, for example, cinoxacin, ofloxacin, diprofloxacin, ofloxacin, sparfloxacin, lomefloxacin, fleroxacin, pefloxacin and amifloxacin, gentamicin, tobramycin, amikacin, netilmicin, kanamycin, and neomycin.

Representative antiviral agents include acyclovir, famciclovir, foscarnet, ganciclovir, idoxuridine, sorivudine, trifluridine, valacyclovir, vidarabine, didanosine, stavudine, zalcitabine, zidovudine, amantadine, interferons, e.g. interferon alpha, ribavirin, rimantadine, nucleoside RT inhibitors such as lamivudine and adefovir, non-nucleoside inhibitors such as nevirapine, delavairidine, Iviride, saquinavir and indinavir, nucleoside DNAP inhibitors such as famciclovir, fialuridine, cidofovir and lobucavir, antisense oligonucleotides such as afovirsen, receptor decoys such as sICAM-1, capsid binding agents such as pirodavir and neuraminidase inhibitors such as GG167.

Specific examples of drugs that are readily absorbed in the upper gastrointestinal tract relative to the lower gastrointestinal tract are acyclovir, ganciclovir, cimetidine, ranitidine, captopril, methyldopa and selegiline.

Specific examples of drugs that exhibit poor solubility in water are diphenidol, meclizine hydrochloride, prochlorperazine maleate, phenoxybenzamine, triethylperazine maleate, anisindone, diphenadione erythrityl tetranitrate, digoxin, isoflurophate, acetazolamide, methazolamide, bendroflumethiazide, chlorpropamide, tolazamide, chlormadionone acetate, phenaglycodol, allopurinol, alluminurri aspirin, methotrexate, acetyl sulfisoxazole, erythromycin, progestins, estrogenic, progestational corticosteroids, hydrocortisone, hydrocorticosterone acetate, cortisone acetate, tramcinolone, methyltestosterone, 17-beta-estradiol, ethinyl estradiol, prazosin hydrochloride, ethinyl estradiol 3-methyl ether, prednisolone, 17-alpha-hydroxyprogesterone acetate, 19-norprogesterone, norgestrel, norethindrone, progesterone, norgestrel and norethynodrel.

Retention of the dosage form of the present invention in the stomach for a prolonged period of time may make it especially useful for the localised treatment of gastric acidity and gastrointestinal disorders such as duodenal ulcers, peptic ulcers and chronic gastritis.

Representative drugs for such localised treatments include cimetidine, ranitidine, famotidine, nizatidine, zolentine, omeprazole, lansoprazole and active agents useful for the treatment of *Helicobacter pylori*, such as metronidazole, tinidazole, amoxicillin, clarithromycin, minocycline and tetracycline.

The dosage form of the present invention is particularly suited to the administration of drugs against *Helicobacter pylori*, e.g. antibiotics as exemplified by minocycline which are able to penetrate the space between the inner stomach lining and the stomach protective mucous layer where the *Helicobacter pylori* organism is present, with the result of eradicating the *Helicobacter pylori* organism either totally or to such a degree that relapse after treatment for a large portion of the treatment population may be minimised. The increased residence time of the dosage form provided by this invention in the stomach permits a drug delivery period at the situs of the organism that is longer than that provided by conventional tablets and capsules. The increased efficiency and efficacy of treatment afforded by the present invention may allow one to treat gastric disorders in a large number of subjects with dosage forms having a single drug, for example minocycline. Accordingly, more complicated treatment regimens may be avoided.



Other drugs exhibiting a narrow absorption window, preferably in the portion of the gastro intestinal tract adjacent the duodenum, such, for example, as alfluzosine, prazosin, ketanserin, guanabenz acetate, captopril, captopril  
5 hydrochloride, enalapril, enalapril maleate, lysinopril, hydralazine, methyldopa, methyldopa hydrochloride, levodopa, carbidopa, benserazide, amlodipine, nitrendipine, nifedipine, nicardipine and verapamil, may be employed in the present invention.

10

Said inner core may comprise about 10 to 90% by weight of the total dosage form, more particularly about 60% wt.

15

Said intermediate layer may comprise porous excipients that are water insoluble or poorly water soluble, e.g.

20

hydrophobic, waxy and/or fatty excipients. Such excipients include: any of the known hydrophobic cellulosic derivatives and polymers including alkylcellulose, e.g. ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose,  
20 carboxymethylcellulose and derivatives thereof; polymethacrylic polymers, polyvinylacetate and cellulose acetate polymers; fatty acids or their esters or their salts; fatty alcohols; polyoxyethylene alkyl ethers; polyoxyethylene stearates; sugar esters; lauroyl macrogol-32 glyceryl,  
25 stearyl macrogol-32 glyceryl and the like.

30

Other excipients providing a waxy, hydrophobic quality to the intermediate layer may be chosen from waxy substances such as carnauba wax, paraffin, microcrystalline wax, beeswax, cetyl ester wax and the like; non-fatty hydrophobic substances such as calcium phosphate salts, e.g. dibasic calcium phosphate may also be employed. Preferred ingredients for use in the intermediate layer include glyceryl behenate and dibasic calcium phosphates.

The aforementioned excipients may provide from 50 to 100% by weight of the constituents of the intermediate layer; more particularly from 80 to 100% wt.

5

The intermediate layer preferably comprises from 50 to 80% by weight of the dosage form, more particularly about 70% wt., and may serve to provide the microspheres with all or at least a substantial part of their buoyancy in aqueous media.

10

Said outer coating may comprise a film-forming polymer. Said film-forming polymer may be selected from any of those film-forming polymers known to those skilled in the art to be release-rate controlling. A characteristic of the outer coating is that it preferably comprises at least one water-insoluble polymer. Typical of such a polymer is alkylcellulose; more particularly ethylcellulose. Suitable ethylcellulose polymers include those available under the trade name SURELEASE<sup>®</sup>, e.g. SURELEASE<sup>®</sup> E7-19070, available as a plasticised aqueous dispersion with oleic acid and medium chain triglycerides from Colorcon Limited, Dartford, UK. Other suitable ethylcellulose polymers include the various polymers known and available as film-forming polymers under the ETHOCEL<sup>®</sup> marks (Anstead International, Basildon, UK).

25

Other release rate-controlling film-forming polymers may also be employed, such as methacrylic acid methacrylic acid ester copolymers. The Eudragit<sup>®</sup> (Röhm GmbH & Co. KG, Darmstadt, Germany) coating polymers are a family of methacrylic copolymers, and those release rate-controlling members are useful in dosage forms of the present invention, e.g. the non-pH dependant RL 30D [poly(ethyl acrylate-co-methyl

30

methacrylate-cotrimethylammonioethyl methacrylate chloride)] and RS 30D [poly(ethyl acrylate-co-methyl methacrylate-cotrimethylammonioethyl methacrylate chloride)] grades.

5 Given that the outer coating comprises a water-insoluble polymer, the ability and extent to which the outer coating controls the rate of release of active substance may depend on the thickness of said outer coating, as this in turn will affect the rate of ingress of moisture through the coating,  
10 and the rate of egress of drug substance. Said rate of release may be proportional to the thickness of said outer coating.

The thickness of said outer coating may be influenced by the  
15 amount of film-forming polymer employed. Preferably, the outer coating may employ at least one film-forming polymer in amounts of about 10 to 90% by weight based on the total weight of the dosage form.

20 The rate of release of drug through the coating may be influenced by the packing of the polymer chains, drug being able to be released through interstitial spaces in the polymer matrix. However, drug release rate can also be affected by the inclusion of small amounts of water-insoluble  
25 or water-soluble substances in the outer coating. Water-soluble substances may be washed out of the outer coating to form pores or channels through the insoluble polymer through which drug substance can pass. Water-soluble excipients for this purpose are well known in the art, and include well-  
30 known pore and channel formers such as lactose, HPMC, mannitol, sugars and the like. The water-insoluble excipients for this purpose may act by disrupting the polymer matrix, creating faults therein through which drug substance can pass. Water-insoluble excipients for this purpose are well-

known in the art and include such materials as talc,  
dicalcium phosphate and the like. The amount of such  
excipients may vary between 1 and 50% by weight based on the  
weight of the outer coating, depending on the desired release  
5 rate.

The outer coating may be applied directly to the intermediate  
layer, but in some embodiments the intermediate layer may  
have an irregular surface; for example it may be pitted with  
10 cracks, fissures or the like as a result of the manufacturing  
process. When an outer coating is applied directly to such an  
irregular surface, the depth of coating at different points  
on the dosage form is likely to vary somewhat. This variance  
of outer coating thickness may have a deleterious effect on  
15 the rate of release of a drug substance from the dosage form.

In a preferred embodiment the dosage form contains a film  
coating disposed between said intermediate layer and said  
outer coating. The film coating's primary function is to  
20 present a smoother surface on which said outer coating may be  
applied in order to ensure maximal uniformity of the  
thickness of the outer coating. Suitable materials for  
inclusion in the film coating include such film-forming  
polymers as are known in the art for use in aesthetic  
25 coatings, by which is meant any of those film-forming  
polymers used to coat dosage forms to give them a smooth  
and/or glossy finish.

Such film coatings may comprise at least one  
30 hydroxypropylmethylcellulose polymer of the kind typically  
employed in film coatings. In particular the OPADRY<sup>®</sup>  
hydroxypropylmethylcelluloses available from Colorcon  
Limited, Dartford, UK may be employed, especially OPADRY<sup>®</sup>  
YS-1-7003. Other polymers such, for example, as

polyvinylalcohol, e.g. OPADRY<sup>®</sup> AMB type, and waxy polymer coatings such, for example, as the OPAGLOS<sup>®</sup> type may also be employed. Alternatively, a sugar coating could be employed as a film-forming layer, alone or in combination with other  
5      aforementioned film forming polymers.

When employed, the film coating may be present in an amount of 1 to 80% by weight based on the total weight of the formulation; more preferably 3 to 10% wt.

10

Preferably the outer coating does not contain any component that is mucoadhesive, i.e. it does not contain - or is substantially free of - any excipient the purpose or function of which is to stick to the stomach mucosa and thereby delay  
15      transit of the dosage form through the stomach.

20

The dosage form of the present invention may contain one or more additional excipients that are conventionally employed in the formulation of solid oral dosage forms, e.g. diluents and fillers which add bulk to a formulation and enable dosage forms of desired size and shape to be formed, binders which promote the adhesion of constituent particles of a formulation to maintain its integrity, colourants,  
25      flavourants and preservatives.

25

The dosage form of the present invention is presented as a solid oral dosage form. In some embodiments it may be presented as a capsule containing a plurality of beads. Alternatively, said particles may be compressed with commonly  
30      available tablet excipients to form a compressed dosage form. In yet another embodiment the particles may be contained in a sachet form.

The size of the particles may depend upon the process(es) used to form them and the conditions employed in such processes. However, particles having a diameter of at least about 0.1 mm and up to about 2 mm are desirable and can easily be prepared using a method described below for example. In some embodiments at least 90% wt. of the particles may have an effective diameter of at least 0.1 mm but no more than 2 mm. Where the particles are spherical then their effective diameter is their actual diameter, but for non-spherical particles the "effective diameter" may be determined using reticulated screens or meshes having known pore sizes.

The particles of the dosage form of the present invention are of low density. Such low density may contribute to the slow transit time of the dosage form. By "low density" here is meant that the particles may have an average density of about 1 g/cm<sup>3</sup> or less. In some embodiments at least 90% wt. of the particles, preferably at least 95% wt., have a density of about 1 g/cm<sup>3</sup> or less. As mentioned above, the particles according to the present invention are buoyant. For example, when placed in a beaker containing still aqueous media, e.g. water, the particles may float on the surface of such medium for a period in excess of twelve hours. It will be appreciated that gastric fluid may have a density that is greater than that of water, and furthermore the GI tract presents a turbulent environment in which particles may be continually displaced. Accordingly, in some embodiments, the particles may be slightly more dense than water, but still have the requisite buoyancy in gastric media for the purposes of the present invention. Thus, said particles may have an average specific gravity (relative to water) of up to about 1.1, and preferably at least 90% wt., more preferably 95%

wt., of the particles have an individual specific gravity of about 1.1 or less.

5 The dosage form of the present invention may dissolve in aqueous media to release a drug substance with a release profile that is zero order or substantially zero order. By "zero order" here is meant that the rate of release of the drug is constant over time. Desired release profiles, whereby at least 80% wt. of the drug is released with zero order or  
10 substantially zero order, may be obtained with the dosage form of the present invention.

Release profiles may be measured using the compendial test methods and apparatus (See for example the U.S. Pharmacopeia  
15 ("USP") 26 National Formulary ("NF") 21 "771 Dissolution Test"). A test described therein is the USP Method II (the so-called "Paddle Method"). Dissolution data and release profiles can be obtained using these methodologies, albeit with some modification in dissolution medium having regard to  
20 the nature of the drug substance. In a medium consisting of 600 ml of a 50 mM acetate buffer at pH 4.5 and a paddle speed of 100 rpm, 80% wt. of drug release may occur within 2 to 12 hours, depending on the thickness of the outer coating.

25 The particles may be modified to achieve other drug release profiles. For example, the particles may be over-coated with an additional drug-containing layer to obtain pulsatile delivery, whereby the drug in said over-coated layer (which may be the same or different from the drug(s) within the  
30 particles) is released according to a first release profile, and said drug or drugs within the particles are released according to a second release profile.

Additionally or alternatively, the particles may be over-coated with an enteric coating to delay release of drug substance.

5 Modification of the release profile of drug from the particles may also be achieved by means of an encapsulating medium surrounding the particles. In particular, a capsule or tablet containing the particles may be adapted to delay or retard the release of the drug or drugs from the particles.  
10 In some embodiments said tablets or capsules may contain or carry a drug substance externally of the particles, which drug substance may be released with a first release profile before the drug or drugs are released from the particles according to a second release profile.

15

The dosage form of the present invention may find utility in the treatment or prevention of disease states in mammals depending on the drug or drugs that are employed. For the above-mentioned lists of drugs, the disease states that may  
20 be treated or prevented are those against which such drugs are known to be effective.

The amount of drug that may be employed in the dosage form may depend upon the drug used, the disease state(s) to be  
25 treated and the condition of the patient, but it may be in the range of 0.01 mg to 1g. By way of example, suitable daily doses are in the range of 0.01 mg to 5g, depending on the drugs to be employed.

30 The dosage form may be dosed once or more times daily depending on the condition(s) to be treated.

According to a further aspect of the invention there is provided a method of treatment or prophylaxis of a disease



state which comprises administering to a patient in need of such treatment or prophylaxis a dosage form according to the present invention, said dosage form including at least one drug that is effective against said disease state.

5

The dosage form of the present invention has the advantage that it may deliver said at least one drug to specific absorption sites of the GI tract in mammalian subjects.

10

Moreover, given that the dosage form is presented in multiparticulate form, variability in the dosing is likely to be ameliorated: In the event of one of the particles failing to exhibit a prolonged gastric residence time, only a small fraction of the total delivered dose would be delivered to the patient in an uncontrolled manner.

15

The dosage form of the present invention may have the additional advantage that it can be prepared using established pharmaceutical processing methods with materials that are approved for use by the relevant pharmaceutical regulatory authorities.

20

25

A method of preparing the dosage form of the present invention provides yet another aspect of the invention. Said inner core may be built up using a fluid bed drier equipped with a rotogranulator insert according to techniques known in the art. Alternatively, extrusion spheronisation techniques may be employed.

30

Said intermediate layer may be built up using a fluid bed drier equipped with a rotogranulator insert according to techniques known in the art.

Said coating step(s) may be carried out using conventional film-coating techniques in a fluidized bed apparatus.

An assemblage of inner cores may be formed by charging a rotogranulator (e.g. a Glatt GPCG1 fluid bed dryer, Glatt GmbH, Weimar, Germany) with the constituents of the inner core in powder form. The bed of powder may then be set in centrifugal motion, and a binding solution, e.g. an aqueous solution of PVP, entered into the rotogranulator tangentially; the core particles may be built up in a manner known *per se*.

10

Said intermediate layer may be applied to said inner cores in a rotogranulator. The inner cores may be fluidized in a rotogranulator equipped with an ACCURATE<sup>®</sup> system (Accu-Rate, Inc., Whitewater, WI, USA). Binding solution and the constituents of said intermediate layer in powder form may be fed into the rotogranulator, such that the intermediate layer is built up in a manner known *per se*.

15

The inner cores coated with said intermediate layer may then be transferred to a fluid bed drier, and the coating or coatings applied according to techniques known in the art; for example, said fluid bed drier may be equipped with Würster cylinder.

20

There now follows are series of examples that serve to illustrate the present invention with reference to the accompanying drawing in which the sole figure is a graph of the release profiles of four different formulations in accordance with the invention.

25

30

Example 1

	<u>Inner core</u>	<u>mg</u>	<u>%</u>
	Diltiazem HCl	60	2.78
5	Methocel <sup>®</sup> K100M	180	8.35
	Avicel <sup>®</sup> PH102	120	5.57
	Compritol <sup>®</sup> 888ATO	240	11.14
	Plasdone <sup>®</sup> K29-32	29.3	1.36
10	<u>Intermediate layer</u>		
	Methocel <sup>®</sup> K100M premium	709.53	32.92
	Compritol <sup>®</sup> 888 ATO	709.53	32.92
	Plasdone <sup>®</sup> K29-32	106.77	4.95
15	<u>Outer Coating</u>		
	Opadry <sup>®</sup> YS-1-7003	215.51	10.00
	Surelease <sup>®</sup> E7-19070	431.00	20.00

20 Diltiazem HCl, Methocel<sup>®</sup> K100M, Avicel<sup>®</sup> PH102 and Compritol<sup>®</sup>  
 888ATO are sieved and added to a rotogranulator (GPCG1,  
 Glatt) to form a powder bed. The powder bed is set into  
 centrifugal motion and a binder solution consisting of 5% w/w  
 solution of Plasdone<sup>®</sup> K29-32 in water is fed into the  
 rotogranulator as a tangential spray. The inner cores thus  
 25 formed are dried by feeding hot air at a temperature of 65°  
 centigrade into the granulator until the cores reach a  
 temperature of 35° centigrade.

30 The inner cores formed above now form a powder bed which is  
 set in centrifugal motion in the rotogranulator equipped with  
 an ACCURATE<sup>®</sup> system. The powder constituents of the

intermediate layer are fed into the granulator tangentially using the ACCURATE<sup>®</sup> system, as is the binder solution (consisting of 5% w/w Plasdone<sup>®</sup> K29-32 in water). The intermediate layer is built up in this manner, and the particles are dried in a similar manner to that described above.

The particles thus formed are transferred to a fluidized bed drier equipped with a Würster Cylinder. The particles are fluidized by an air flow passing up through the base plate of the drier and the coating solution is fed into the drier in a direction concurrent with the air flow. The coated particles are dried in an air flow at 60° centigrade until they reach a temperature of no more than 40 to 42° centigrade to provide an assemblage of coated particles forming a dosage form in accordance with the present invention.

#### Example 2

To determine the *in vitro* release characteristics of the formulation described above and additional formulations substantially the same as the formulation described above differing only in the quantities of Surelease<sup>®</sup> ethylcellulose in their outer coatings (15% wt., 25% wt. and 30% wt.), standard equipment was used as defined and described in United States Pharmacopoeia USP XXIII, chapter 711, page 1792, paragraph "Apparatus 2". This equipment had a stirring paddle comprising a blade and a shaft and was operated at 100 rpm. Dissolution was investigated at 37° centigrade in 600 ml of a dissolution medium made up of 0.1 M acetate buffer of pH 4.5. The release of the active substance was monitored by UV spectrophotometry at 278 nm.

The results are illustrated in the accompanying figure as respective time profile diagrams for the four formulations.

5 For each formulation the following was observed on the *in vitro* release characteristics:

The first release of active substance takes place within a release period of less than one hour.

10

By adjusting the outer coating coat weight it is possible to modulate the release rate such that at least 80% wt. of drug is released between 1 hour and about 15 hours. Furthermore, release of at least 80% wt. of drug is achieved with

15

substantially zero order kinetics.

Claims:

1. A dosage form comprising a plurality of particles that are buoyant in aqueous media, each particle comprising a drug-containing inner core, an intermediate layer surrounding the core and a drug release rate-controlling outer coating.
2. A dosage form according to claim 1, further comprising a coating disposed between said intermediate layer and said drug release rate-controlling outer coating.
3. A dosage form according to claim 1 or claim 2, wherein said inner core comprises at least one matrix-forming polymeric material and at least one drug.
4. A dosage form according to claim 3, wherein said at least one matrix forming polymer is selected from:  
hydroxypropylcellulose and hydroxypropylmethylcellulose;  
poly(ethylene)oxide; ethylcellulose; methylcellulose;  
carboxymethylcellulose; hydrophilic cellulose derivatives;  
polyethylene glycol; polyvinylpyrrolidone; cellulose acetate;  
cellulose acetate butyrate; cellulose acetate phthalate;  
cellulose acetate trimellitate; polyvinylacetate phthalate;  
hydroxypropylmethylcellulose phthalate;  
hydroxypropylmethylcellulose acetate succinate; poly(alkyl methacrylate); carboxyvinyl polymers; polyvinyl alcohols;  
glucans; scleroglucans; chitosans; mannans; galactomannans;  
xantan gums; carrageenin; carrageenans; amylose; alginic acid, and salts and derivatives thereof; and poly (vinylacetate).
5. A dosage form according to any of claims 1 to 4, wherein said intermediate layer comprises at least one water-insoluble or poorly soluble polymer and at least one waxy or fatty material.

6. A dosage form according to claim 5, wherein said waxy or fatty material is a hydrophobic cellulosic derivative or polymer selected from: ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose and derivatives thereof; polymethacrylic polymers, polyvinylacetate and cellulose acetate polymers; fatty acids or their esters or their salts; fatty alcohols; polyoxyethylene alkyl ethers; polyoxyethylene stearates; sugar esters; lauroyl macrogol-32 glyceryl, stearyl macrogol-32 glyceryl; carnauba wax, paraffin, microcrystalline wax, beeswax, cetyl ester wax; non-fatty hydrophobic substances such as calcium phosphate salts and glyceryl behenate.
7. A dosage form according to any of claims 1 to 6, wherein said outer coating contains a release rate-controlling polymer.
8. A dosage form according to claim 7, wherein said release rate-controlling polymer is selected from ethylcellulose and methacrylic acid-methacrylic acid ester copolymers.
9. A dosage form according to claim 8, wherein said polymer is selected from SURELEASE<sup>®</sup> E7-19070, ETHOCEL<sup>®</sup> film-forming polymers and Eudragit<sup>®</sup> coating polymers.
10. A dosage form according to claim 2, wherein said coating disposed between said intermediate layer and said drug release rate-controlling outer coating contains at least one polymer selected from hydroxypropylmethylcellulose and polyvinylalcohol.
11. A dosage form according to claim 10, wherein said polymer is selected from OPADRY<sup>®</sup> YS-1-7003, OPADRY<sup>®</sup> AMB type film coating polymers and OPAGLOS<sup>®</sup> type film coating polymers.

12. A dosage form according to any of claims 1 to 11 in the form of a compressed tablet, capsule or sachet comprising a plurality of buoyant particles.

5 13. A dosage form according to any of claims 1 to 12, wherein said at least one drug is selected from drugs that can be released and absorbed or act locally in the stomach or that can be released and absorbed in the portion of the intestine proximate to the duodenum.

10

14. A dosage form according to claim 13, wherein said at least one drug is selected from: sulfonamides, quinolones, penicillins, cephalosporins, aminoglycosides and tetracyclines; beta-lactam antibiotics, vancomycin, clindamycin, erythromycin, trimethoprim-sulfamethoxazole, rifampin, ciprofloxacin, amoxicillin, clindamycin, ceftriaxone, cefotaxime, chloramphenicol, clindamycin, cefoxitin, doxycycline, spectinomycin, ofloxacin, rifampin, minocycline, doxycycline, aztreonam, imipenem, meropenem, nitrofurantoin, azithromycin, atovaquone, trimetrexate, dapsone, primaquin, trimetrexate, ketoconazole, fluconazole, amphotericin B, itraconazole, trifluridine, foscarnet, zidovudine, amantadine, interferon alfa, sulfonamides selected from sulfisoxazole, sulfadiazine, and sulfasalazine; quinolones and fluoroquinolones selected from cinoxacin, ofloxacin, diprofloxacin, ofloxacin, sparfloxacin, lomefloxacin, fleroxacin, pefloxacin, amifloxacin, gentamicin, tobramycin, amikacin, netilmicin, kanamycin, and neomycin; acyclovir, famciclovir, foscarnet, ganciclovir, idoxuridine, sorivudine, trifluridine, valacyclovir, vidarabine, didanosine, stavudine, zalcitabine, zidovudine, amantadine, interferons, ribavirin, rimantadine, nucleoside RT inhibitors selected from lamivudine and adefovir; non-nucleoside inhibitors selected from nevirapine, delamanid, efavirenz, saquinavir and indinavir; nucleoside DNA polymerase inhibitors selected from famciclovir,

30




fialuridine, cidofovir and lobucavir; antisense oligonucleotides; receptor decoys; capsid binding agents; neuraminidase inhibitors; acyclovir, ganciclovir, cimetidine, ranitidine, captopril, methyldopa selegiline, diphenidol, 5 meclizine hydrochloride, prochlorperazine maleate, phenoxybenzamine, triethylperazine maleate, anisindone, diphenadione erythryl tetranitrate, digoxin, isofilurophate, acetazolamide, methazolamide, bendroflumethiazide, chlorpropamide, tolazamide, chlormadionone acetate, 10 phenaglycodol, allopurinol, alluminurri aspirin, methotrexate, acetyl sulfisoxazole, erythromycin, progestins, esterogenic, progestational corticosteroids, hydrocortisone, hydrocorticosterone acetate, cortisone acetate, tramcinolone, methyltestosterone, 17-beta-estradiol, ethinyl estradiol, prazosin 15 hydrochloride, ethinyl estradiol 3-methyl ether, prednisolone, 17-alpha-hydroxyprogesterone acetate, 19-norprogesterone, norgestrel, norethindrone, progesterone, norgesterone, norethynodrel, cimetidine, ranitidine, famotidine, nizatidine, zolentine, omeprazole, lansoprazole, metronidazole, timidazole, 20 amoxicillin, clarithromycin, minocycline, tetracycline, alfluzosine, prazosin, ketanserin, guanabenz acetate, captopril, captopril hydrochloride, enalapril, enalapril maleate, lysinopril, hydralazine, methyldopa, methyldopa hydrochloride, levodopa, carbidopa, benserazide, amlodipine, nitrendipine, 25 nifedipine, nicardipine, and verapamil.

15. A method of treatment or prophylaxis of a disease state which comprises administering to a patient in need of such treatment or prophylaxis a dosage form as claimed in claim 1, 30 said dosage form including a drug that is effective against said disease state.

16. A dosage form as claimed in claim 1 and substantially as described herein.

17. A method of preparing a dosage form as claimed in claim 1 substantially as described herein.



INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2005/013670

**A. CLASSIFICATION OF SUBJECT MATTER**  
A61K9/50 A61K31/55

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**  
Minimum documentation searched (classification system followed by classification symbols)  
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)  
EPO-Internal, WPI Data, EMBASE, BIOSIS, FSTA

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 474 786 A (KOTWAL ET AL) 12 December 1995 (1995-12-12) column 5 - column 6; example 1	1-13, 15-17
X	US 6 284 271 B1 (LUNDBERG PER JOHAN ET AL) 4 September 2001 (2001-09-04) column 8 - column 9; example 2	1-7, 12-17
X	US 5 472 712 A (OSHLACK ET AL) 5 December 1995 (1995-12-05) column 17; example 1 column 32 - column 33; examples 15-17	1-7, 12, 13, 15-17
X	US 6 322 819 B1 (BURNSIDE BETH A ET AL) 27 November 2001 (2001-11-27)  column 9, line 15 - line 39 column 10 - column 11; examples 1-4	1, 3, 5-9, 12, 13, 15-17
	-/--	

Further documents are listed in the continuation of Box C.       See patent family annex.

\* Special categories of cited documents :

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>
--	--

Date of the actual completion of the international search  10 March 2006	Date of mailing of the international search report  22/03/2006
--	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Schüle, S
---	-------------------------------------

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2005/013670

## C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 207 197 B1 (ILLUM LISBETH ET AL) 27 March 2001 (2001-03-27) claims 1-7	1, 3, 5-7, 13-17
X	US 5 639 476 A (OSHLACK ET AL) 17 June 1997 (1997-06-17) column 27 - column 28; example 11	1-7, 12, 13, 15-17
X	US 5 817 338 A (BERGSTRAND ET AL) 6 October 1998 (1998-10-06) column 10; example 2 column 13; example 9	1-7, 12-17
X	WO 01/58424 A (WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTRE) 16 August 2001 (2001-08-16) claims 1, 3, 9, 11, 14, 15	1-7, 13, 15-17

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2005/013670

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claim 15 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2005/013670

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5474786	A	12-12-1995	AT 196250 T	15-09-2000
			AU 703151 B2	18-03-1999
			AU 1999595 A	09-10-1995
			CA 2185893 A1	28-09-1995
			DE 69518839 D1	19-10-2000
			DE 69518839 T2	22-02-2001
			DK 760655 T3	13-11-2000
			EP 0760655 A1	12-03-1997
			ES 2151594 T3	01-01-2001
			GR 3034971 T3	28-02-2001
			JP 9510709 T	28-10-1997
			PT 760655 T	29-12-2000
			WO 9525506 A1	28-09-1995
			US 5395626 A	07-03-1995
			ZA 9502343 A	23-09-1996
			US 6284271	B1
AU 733801 B2	24-05-2001			
AU 8135798 A	25-01-1999			
CA 2294744 A1	14-01-1999			
DE 69817587 D1	02-10-2003			
DE 69817587 T2	24-06-2004			
EP 1014952 A1	05-07-2000			
JP 2002508781 T	19-03-2002			
WO 9901112 A1	14-01-1999			
US 5472712	A	05-12-1995		
			AU 652871 B2	08-09-1994
			AU 3002492 A	01-07-1993
			BR 9202982 A	29-06-1993
			CA 2061824 A1	25-06-1993
			DE 69231415 D1	12-10-2000
			DE 69231415 T2	29-03-2001
			DK 548448 T3	22-01-2001
			EG 20083 A	31-05-1997
			EP 0548448 A1	30-06-1993
			ES 2152221 T3	01-02-2001
			FI 921548 A	25-06-1993
			GR 3034951 T3	28-02-2001
			HK 1005686 A1	09-02-2001
			IE 920795 A1	30-06-1993
			IL 101080 A	05-12-1996
			JP 3061474 B2	10-07-2000
			JP 7165609 A	27-06-1995
			KR 252188 B1	01-05-2000
			MX 9200932 A1	01-06-1993
			NO 925016 A	25-06-1993
			NZ 241660 A	26-05-1993
			PT 548448 T	30-03-2001
SG 44703 A1	19-12-1997			
US 5273760 A	28-12-1993			
ZA 9201366 A	30-12-1992			
US 6322819	B1	27-11-2001	AU 1214500 A	08-05-2000
			CA 2348090 A1	27-04-2000
			EP 1123087 A1	16-08-2001
			JP 2002527468 T	27-08-2002
			WO 0023055 A1	27-04-2000

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2005/013670

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6322819	B1	US 2001055613 A1 US 6605300 B1	27-12-2001 12-08-2003
US 6207197	B1	27-03-2001	
		AT 270880 T	15-07-2004
		AU 737818 B2	30-08-2001
		AU 7664298 A	11-12-1998
		BR 9809453 A	20-06-2000
		CA 2285580 A1	26-11-1998
		CN 1257425 A	21-06-2000
		DE 69825049 D1	19-08-2004
		DE 69825049 T2	21-07-2005
		EP 0984774 A1	15-03-2000
		ES 2226137 T3	16-03-2005
		WO 9852547 A1	26-11-1998
		GB 2341550 A	22-03-2000
		HU 0002935 A2	28-12-2000
		JP 2001525848 T	11-12-2001
		NO 995753 A	24-11-1999
		NZ 338105 A	27-04-2001
		PL 336037 A1	05-06-2000
		PT 984774 T	30-11-2004
		SK 148999 A3	11-07-2000
		ZA 9804379 A	22-11-1999
US 5639476	A	17-06-1997	NONE
US 5817338	A	06-10-1998	
		AT 206044 T	15-10-2001
		AU 695966 B2	27-08-1998
		AU 2993795 A	09-02-1996
		BR 9506018 A	02-09-1997
		CA 2170647 A1	25-01-1996
		CN 1134666 A	30-10-1996
		CY 2254 A	04-07-2003
		CZ 9600732 A3	17-07-1996
		DE 69522921 D1	31-10-2001
		DE 69522921 T2	11-04-2002
		DE 723436 T1	11-09-1997
		DK 723436 T3	26-11-2001
		DZ 1906 A1	17-02-2002
		EE 3305 B1	15-12-2000
		EP 0723436 A1	31-07-1996
		ES 2100142 T1	16-06-1997
		FI 961057 A	29-03-1996
		GR 97300014 T1	31-05-1997
		HK 1008300 A1	12-04-2002
		HR 950349 A1	30-06-1997
		HU 75775 A2	28-05-1997
		IL 114450 A	22-09-1999
		JP 9502739 T	18-03-1997
		JP 3350054 B2	25-11-2002
		MA 23607 A1	01-04-1996
		NO 960950 A	07-03-1996
		NZ 289948 A	27-07-1997
		PL 313387 A1	24-06-1996
		PT 723436 T	28-02-2002
		RU 2160094 C2	10-12-2000
		WO 9601623 A1	25-01-1996
		SK 30196 A3	10-09-1997



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2005/013670

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5817338	A	TR 960033 A2 TW 450813 B ZA 9505548 A	21-06-1996 21-08-2001 08-01-1996
WO 0158424	A	16-08-2001 AU 3202001 A	20-08-2001